Although venetoclax and other BCL-2 inhibitors are approved for use in several blood cancers [165,166], the effect of these inhibitors on telomere length values in CML remains unknown. Here, BCL2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.